Clinical phase Alzheimer’s disease drugs 2024, by sponsor
As of January 1, 2024, nearly 80 percent of all Alzheimer’s disease drugs in clinical trial phases 1, 2, and 3 combined worldwide were sponsored by the biopharma industry. This statistic illustrates the trial sponsors of Alzheimer’s disease drugs in development worldwide, by sponsor.